Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In a 32-week exploratory extension of the Phase 2b VESPER-1 study, Pfizer reported a 15.9% non-placebo-adjusted weight loss on 2.4 mg weekly berobenatide, and said no plateau was observed at 32 weeks
Further research is warranted to elucidate underlying mechanisms and optimize patient selection
It was a coordinated recalibration across multiple state affiliates, each arriving at the same conclusion independently: the current trajectory of GLP-1 spending was unsustainable under existing premium structures
Patients should be counseled never to administer extra doses to make up for missed doses, as this could increase the risk of adverse effects without providing additional therapeutic benefit
US$ 21.29
US$ 22.61
US$ 26.13
US$ 21.23
US$ 29.44
US$ 22.71
US$ 24.74
US$ 24.07
US$ 26.51
